Should I buy Incyte (INCY) stock or is it too late?

Incyte · Health Care · price $128

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: BMO Capital — 73% of its targets hit on this sector (239 calls tested). It aims for $130 (+1.8 %), call made on July 30, 2026, maturing on July 30, 2027 (29 d ago).

The 12 reliable analysts $134+4.5 %

The 6 other firms $104-19 %

How to read it: the 12 reliable firms are not filtered by optimism — 8 aim above the price, 4 below, hence their $134 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Incyte

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Jefferies	71 %	+59.1 %	7	$94 -26%
Barclays	67 %	+22.9 %	6	$139 +9%
Oppenheimer	67 %	+16.3 %	12	$90 -30%
Truist Securities	67 %	+10.8 %	6	$105 -18%
RBC Capital	50 %	+1.1 %	6	$109 -15%
Morgan Stanley	67 %	-15.8 %	6	$104 -19%
BMO Capital	14 %	-21.9 %	7	$130 +2%
B of A Securities	57 %	+34.6 %	7	—

In short — Should you invest in Incyte? Is it too late, still worth it? Analysts are split (44% buy, median target $118, i.e. -8%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

6 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
Reasonable valuation (P/E ~16) relative to its sector.

⚠️ Reasons to hesitate

Even the most reliable firm on INCY, JP Morgan (100% hit rate, 3 scored calls), only targets $110 (call made on July 23, 2026, maturing on July 23, 2027) (-14%) in its most recent call. The stock may already have run past its target.
The consensus is not unanimous: of 18 ratings, 10 are neutral.
Limited upside: the median target is only -8% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on INCY

Median target $118 (-8%) · 18 ratings · Hold consensus

Strong Buy00%

Buy844%

Hold1056%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Incyte now?

We won't decide for you. The facts: 44% of analysts rate it a buy, median target $118 (-8%), and JP Morgan (most reliable on INCY, 100%) targets $110. Weigh that against valuation (P/E ~16). This is not personalized advice.

Is it too late to invest in Incyte?

The stated upside is small: the median target ($118) sits just -8% from the price ($128) (most reliable on INCY: JP Morgan, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Incyte still worth investing in?

It depends on the gap between the price ($128) and its estimated value: analysts target $118 on median (-8%), with 44% buys (most reliable on INCY: JP Morgan, 100%). Cross-check with their real reliability on INCY and the cautions above. Information, not advice.

What's the main risk in buying INCY?

Even the most reliable firm on INCY, JP Morgan (100% hit rate, 3 scored calls), only targets $110 (call made on July 23, 2026, maturing on July 23, 2027) (-14%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full Incyte profile (consensus, analyst reliability, price target, performance).